The question arises if one reason for this low OS of Luminal BMBC and triple-negative BMBC could be that there are more clinically approved HER2+ drugs, which can penetrate the brain and therefore treat BM than for Luminal BC or TNBC. Here, ERBB2 is linked to breast cancer.